RGNX REGENXBIO Inc.
Price Chart
Executive Summary
REGENXBIO reported results of its 2026 Annual Meeting held May 29, 2026, where shareholders elected three Class II directors, ratified PwC as auditor, approved non-executive stock option exchange program, and did NOT approve a similar program for executives. The company commenced the non-executive option exchange program on June 3, 2026, with an offer period running through July 1, 2026. This is a routine governance and compensation event with no material financial impact disclosed.
Actionable Insight
Monitor the tender offer statement expected to be filed June 3, 2026 for detailed terms of the option exchange. The rejection of executive option exchange suggests potential retention risk for senior management, but no immediate trading catalyst.
Key Facts
- Annual Meeting held May 29, 2026 with 42,818,883 shares represented (~82.95% of eligible shares)
- Shareholders elected Jean Bennett, A.N. Jerry Karabelas, and Daniel Tass as Class II directors
- Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026
- Approved non-executive employee stock option exchange program (26.4M for, 8.9M against)
- Did NOT approve executive stock option exchange program (14.1M for, 21.0M against)
- Non-executive option exchange program commenced June 3, 2026; offer period ends July 1, 2026
- Exchange program applies to options with exercise price ≥ $18.00; new options priced at fair market value on grant date
- Company states exchange program not expected to result in significant change to stock compensation expense
Financial Impact
No material financial impact disclosed; company states stock compensation expense not expected to change significantly
Risk Factors
- Executive option exchange rejection may signal dissatisfaction with pay structure or governance
- Option exchange could modestly reduce dilution if underwater options are surrendered
- No financial guidance or operational update provided in this filing
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254590 |
| Document: 0001193125-26-254590-index.html | 0001193125-26-254590 |
| Document: 0001193125-26-254590.txt | 0001193125-26-254590 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
9d ago
|
8-K
| $6.69 $6.88 | ▲ +2.84% | ▲ +2.44% | $6.66 (−0.45%) |
|
May 14, 2026
29d ago
|
8-K
| $6.25 $5.72 | ▼ −8.41% | ▼ −7.18% | $6.66 (+6.65%) |
|
Mar 5, 2026
14w ago
|
8-K
| $8.72 $8.65 | ▼ −0.80% | ▲ +0.51% | $6.66 (−23.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access